Evidence map›Paper›PMID 35207613›Full record

ReviewJournal of personalized medicine2022

Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma: Recent Advances and Outcomes.

Taha Al-Juhaishi, Azra Borogovac, Sami Ibrahimi, Matthew Wieduwilt, Sairah Ahmed

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Taha Al-JuhaishiStephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, USA.
Azra BorogovacStephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, USA.ORCID 0000-0002-5093-1634
Sami IbrahimiStephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, USA.
Matthew WieduwiltStephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, USA.
Sairah AhmedMD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA.ORCID 0000-0001-7302-8299

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hodgkin's lymphoma is a rare yet highly curable disease in the majority of patients treated with modern chemotherapy regimens. For patients who fail to respond to or relapse after initial systemic therapies, treatment with high-dose chemotherapy and autologous hematopoietic stem cell transplantation can provide a cure for many with chemotherapy-responsive lymphoma. Patients who relapse after autologous transplant or those with chemorefractory disease have poor prognosis and represent a high unmet need. Allogeneic hematopoietic stem cell transplantation provides a proven curative therapy for these patients and should be considered, especially in young and medically fit patients. The use of newer agents in this disease such as brentuximab vedotin and immune checkpoint inhibitors can help bring more patients to transplantation and should be considered as well.

Indexed as

allogeneic hematopoietic stem cell transplantautologous hematopoietic stem cell transplanthigh-dose chemotherapyHodgkin’s lymphoma

Identifiers

PMID35207613
PMCPMC8880200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.